Dr Tit Albreht
CanCon Project Coordinator, Institute of Public Health of Republic of Slovenia, Ljubljana, Slovenia
Dr Albreht is Head of the Centre for Analyses of Health Systems, Institute of Public Health of the Republic of Slovenia. He is a researcher in the field of health services research, health policy and health systems research, member of the Scientific Committee of EUPHA, member of Academy Health, member of the Slovenian Preventive Medicine Society - currently also member of its Board and a member of the Health Council of the Ministry of Health of Slovenia.
He is an Associate Professor of Public Health at the Department of Public Health of the Medical Faculty in Ljubljana. He acts as a reviewer of several scientific journals and of projects submitted for funding to the European Commission. He is Project Coordinator for CanCon and was Work Package leader on the European Partnership on Action Against Cancer charged with exploring national cancer plans.
Professor Jean-Pierre Armand
Senior Consultant in Oncology, Gustave Roussy, Cancer Campus Grand Paris, France
Jean-Pierre Armand is a medical oncologist and Senior Consultant at Institute Gustave Roussy and Institute Curie in Paris with a major interest in early drug development and personalised medicine. Prior to this appointment he was the General Director of the Institute Claudius Regaud the comprehensive cancer center in Toulouse from 2007-12 where he was in charge of the construction of a new cancer center.
Dr Armand has (co)authored over 300 medical and scientific peer-reviewed articles and has served on numerous boards including, President of ESMO, Medical Director of FECS/ECCO and President of the French Cancer Society (SFC).
In 2013, he received the nomination of Chevalier of Legion of Honor from the French government.
Professor Mariano Barbacid
Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Dr Barbacid is an international leader in studies involving the molecular basis of cancer. He returned to Spain from the USA in 1998 and established the Centro Nacional de Investigaciones Oncologicas (Spanish National Cancer Research Center), where he served as its first director until 2011.
Mariano is best known as one of three researchers who isolated, for the first time, a human oncogene, H-Ras, leading to a decade-long leadership position in the pharmaceutical industry in the USA, where he worked to fast-track approval of new drugs.
Mariano was a founding member of both the European Academy of Cancer Sciences and the European Research Institute for Integrated Cellular Pathology. In 2007 he was awarded the Medal of Honour by the International Agency for Cancer Research and in 2012 was elected a Foreign Member by the National Academy of Sciences, Washington, DC.
Dr Michele Barzach
IHU Strasbourg Board of Trustees, Strasbourg, France
Dr Barzach has had a long and distinguished career in global health strategy primarily in the fields of research, new technologies, social protection, development, international health cooperation, sustainable development and environmental risks. In 2012 she was appointed as President of UNICEF France.
Michele is a former French Minister of Health and Family Welfare and has held many voluntary positions in international organizations, foundations and associations, including the World Health Organization, the World Bank (Health Department, Nutrition and Population) to Project Hope (Health Opportunities for People Everywhere) and the International Vaccine Initiative (IVIA). She also served for a number of years as a Non-Executive Director of GlaxoSmithKline PLC.
In 2008 Dr Barzach was awarded the Ordre national de la Légion d'honneur by President Nicolas Sarkozy.
Professor Jonas Bergh
Department of Oncology-Pathology, Karolinska Institut, Stockholm, Sweden
Professor Bergh is Professor of Oncology at the Karolinska Institute and, since 2010, Director of the Breast Cancer Network. Between 2009 and 2010 he was Director of the Manchester Breast Cancer Centre.
Jonas’ major research interests include: prognostic and predictive factors in breast cancer aiming at understanding breast cancer biology, factors related to tumour progression, primary cancers versus metastatic disease and personalised medicine.
Professor Bergh has served on a number of boards and committees including Chairman of the Swedish Breast Cancer Group, ECCO Academy Fellow 2010, Member of ASCO Faculty and St Gallen Consensus Panel. In 2010 he was awarded the Distinguished Professor Award by the Karolinska Institute.
Professor David Cameron
Edinburgh Cancer Centre, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom
Professor Cameron is Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian and has responsibility for oversight and strategy of clinical and translational research in cancer in Edinburgh. He was recently appointed as the Chief Scientist’s Office Clinical Cancer Research Champion in Scotland to act as a focal point for current and future clinical research in cancer in Scotland. Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Network.
David’s research interests are focussed on clinical trials in breast cancer and he has been chief investigator on a number of practice changing trials.
He is a present and past member of several cancer research funding committees including INCA PHRC, PEAR, Cancer Research UK Clinical Trials Committee and NIHR funding bodies. He is also a member of several professional societies including the American Society of Clinical Oncology & the European Society for Medical Oncology and a past chairman of the EORTC New Agent Committee.
Professor Pierfranco Conte
Istituto Oncologico Veneto, Padova, Italy
Professor Conte is the Director of The Oncology Institute Oncology Veneto (IOV) of Padua. His medical training took place in Turin and has worked at a number of hospitals in Italy including, most recently, as Director of Modena University Hospital.
Pierfranco’s main research interests are in breast cancer and he has led numerous clinical trials in this and other cancers with a particular interest in translational research and personalised medicine. He has published more than 320 papers in Peer Reviewed Journals.
Professor Conte has served on numerous committees including; the founder and Chairman of the Association of Translational Research Oncology (ASTRO), Vice Chairman of the Cancer Committee, Emilia Romagna Regional Government and a member of the Anti Cancer Drug Committee of the Italian Drug Agency (AIFA).
Professor Filippo de Braud
Medical Oncology Division, National Cancer Institute, Milan, Italy
Professor de Braud, is the Director of the Department and the Division of Medical Oncology at the National Cancer Institute of Milan. Having completed his medical training Professor de Braud spent time at a number of research institutes including the Royal Free Hospital School of Medicine in London, the Institute Gustave Roussy in Paris and Wayne State University in Detroit, MI, USA. He was also Deputy Director of the Division of Medical Oncology at the European Institute of Oncology in Milan
Filippo’s research interests are focussed early clinical trials of new agents and he has authored or co-authored over 220 publications in medical oncology and numerous book chapters.
Professor de Braud has served as scientific consultant and member of national and international committees, including the Ministerial Committee on Medicines of the Ministry of Health and the Scientific Technical Commission.
Professor Aimery de Gramont
Department of Oncology, Franco-British Institute, Levallois Perret, France
Professor Aimery de Gramont has been a Professor of Oncology since 1993 and currently serves as Department Head/Chief of Medical Oncology at the Franco-British Insitute in Paris. He earned his MD degree from the Faculty of Medicine in Paris, France and subsequently continued his training in Paris and Quebec. He moved from Hôpital Saint-Antoine to Franco-Bristish Institute October 2014.
Aimery’s fundamental and preclinical research has focused primarily on the fields of cytogenetics, molecular biology, targeted therapies and adoptive immunotherapy. His clinical research has involved mainly gastro-intestinal and ovarian cancer therapy and he has played a pivotal role in a colon cancer program involving more than 15000 patients since 1984. He has authored or coauthored more than 300 journal articles and been an invited speaker in more than 30 countries.
Professor de Gramont serves as Chairman of the ARCAD foundation and has been GERCOR multidisciplinary cancer research group Chairman for 20 years. He is a member of the American Society of Clinical Oncology, and European Society for Medical Oncology.
Professor Francesco De Lorenzo
Italian Federation of Volunteer-based Cancer Organizations, Rome, Italy
European Cancer Patient Coalition, Brussels, Belgium
Professor de Lorenzo is currently President of the European Cancer Patient Coalition a group which represents the interests of all cancer patient groups with more than 300 members from 44 countries.
Francesco is colon cancer survivor, medical doctor and former Professor of Biochemistry at University Federico II Naples. He has a rich experience in cancer advocacy being the co-founder, former Vice President and Board member of ECPC. He was also engaged in Italian politics as a Member of the Parliament, holding several ministerial mandates.
At the EU and international level, Professor de Lorenzo is member of the ESMO Patient Advisory Group, works in the EPAAC WP9, participates to the European collaborative Group on Cancer Survivorship (ECGCS) where he serves as a member, and he is also a Founding Member of the Elite Oncology Roundtable, created under the auspices of the Society for Translational Oncology – STO, from which the European Cancer Patient’s Bill of Right originated.
Professor Volker Diehl
Internal Medicine, University of Cologne, Köln, Germany
Professor Diehl is Director Emeritus for internal medicine at the University of Cologne, Germany. Amongst numerous positions, he was founder and chairman of the German Hodgkin Study Group (GHSG) for 30 years where he designed and established six generations of consecutive Hodgkin trials, and is now the honorary chairman. In addition, he was founding director of the National Cancer Center in Heidelberg, Germany.
Volker is well known for his pioneering research on Hodgkin lymphoma. His scientific achievements include the discovery of the causative role of the Epstein-Barr virus in infectious mononucleosis and the study of its association with Hodgkin lymphoma. His clinical achievements include design and implementation of the BEACOPP principle for advanced Hodgkin lymphoma; establishment of the International Prognostic Index for advanced Hodgkin lymphoma; and he is co-founder of the European Task Force for Lymphocyte Predominant Hodgkin Lymphoma.
Professor Diehl has received much recognition for his work, including the German Johann Georg Zimmermann Prize for Cancer Research.
Dr Sarper Diler
Myeloma Patients Europe, Istanbul, Turkey
Dr Diler is a Professor at Istanbul University Medical Faculty. His research interests include KIR Genes, HLA polymorphism and disease associations as well as matching in stem cell transplant settings and specialized in biobanking. He is one of the pioneers of biobanking in Turkey.
The loss of his brother from cancer has driven Sarper in the fight against cancer and his current roles include those of President, Myeloma Patients Europe, Director & CEO of KOKDER and on the Board of Directors of the Lymphoma Coalition. He was also the founder member and first president of CancerPlatform of TURKEY, bringing together 12 cancer associations throughout Turkey.
Dr Diler’s reputation, which comes from his academic, medical professional career as well as in the media, has been instrumental in driving pioneering NGO projects on cancer.
Ms Sema Erdem
Europa Donna, Piazza Amendola, Milan, Italy
Sema Erdem is a cancer survivor and experienced patient advocate who, for the past 8 years, has held breast cancer awareness and breast cancer patient advocacy seminars at national and at international meetings. She is a strong supporter of evidence-based practice and in her time of the scientific committee for Europa Donna promoted participation in clinical trials.
Sema was Europa Donna (ED) Vice-President from 2011-13, she is an ECCO PAC member and ED Turkey, Executive Board Member.
Mr Jan Geissler
Leukemia Patient Advocates Foundation, Berne, Switzerland
European Patients Academy on Therapeutic Innovation, Riemerling, Germany
Jan Geissler is a cancer survivor and the Director of the ‘European Patients Academy on Therapeutic Innovation’ (EUPATI), a project funded by the Innovative Medicines Initiative (Public Private Partnership of EU Commission and EFPIA). EUPATI develops educational material and training courses to educate patient representatives and the lay public about all processes involved in medicines development. He is also founder and managing director of Patvocates.
Jan studied at the University of Regensburg (Germany) and Aston University (Birmingham, UK), graduating with a university diploma in business. Jan then worked for the media company Bertelsmann, Germany and in 2003, he joined Vodafone Group R&D where he headed business modelling teams in Germany and The Netherlands. His experience of cancer at the age of 28 years prompted him, in 2008, to leave Vodafone and focus his professional life on patient advocacy.
In 2002, he founded the online patient community Leukämie-Online/LeukaNET, which is one of the most frequented online communities for leukaemia patients in the German speaking Internet today. Jan co-founded the CML Advocates Network and the European Cancer Patient Coalition (a European umbrella association connecting more than 300 cancer patient groups) and became its first full time director (2008-2010).
Today, he is a patient representative in various steering committees and advisory boards, including acting as member of the European Commission Expert Groups on Rare Diseases and the European Commission Expert Group on Cancer Control, as member of the ESMO Patient Advocates Work Group, the ECCO Patient Advisory Committee. He also acts as an independent expert for the EU Commission.
Ms Jola Gore-Booth
EuropaColon & Global Colon Cancer Alliance
Jola Gore-Booth is the CEO of Colon Cancer Concern (now BCUK). She became involved in NGOs as a result of her father dying from lung cancer and helping reduce deaths from cancer has become part of her life’s commitment
Jola has established 21 patient advocacy groups in Europe all of whom are committed to work toward the mission and goals of EuropaColon, a group established and led by Jola, dedicated to uniting patients, caregivers, healthcare professionals, politicians, the media and the public in the fight against the disease. The organisation is currently represented by 40 groups across 31 European countries and has been acknowledged as the voice of colorectal cancer patients in Europe.
Ms Gore-Booth is a member on numerous committees including; the ECPC, ESMO’s Cancer Patient Working Group and ECCO’s Patient Advisory Committee. She also serves on Roche Patient Advisory Board
Mr Geoffrey Henning
Director of Policy, EuropaColon
Geoffrey Henning joined EuropaColon as Director of Policy in 2012. He is an ECCO PAC member. His previous experience includes working in the voluntary sector, where he co-founded and managed a successful national fundraising organisation for HIV. He has also worked on projects with various patient organisations in the UK within his previous roles of Patient Liaison Manager at Roche, and then as Policy Manager for Roche Oncology.
Professor Liselotte Hojgaard
Danish National Research Foundation, Copenhagen, Denmark
Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
Professor Højgaard is Head of Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet and Professor in Medicine and Technology at the University of Copenhagen.
Liselotte is a specialist in clinical physiology and nuclear medicine with research in PET scanning for oncology, pediatrics and methodology. She is a respected academic who has published extensively on these subjects with over 200 peer review publications and 150 other science related articles.
Professor Hojgaard is Chairman of the Board of the Danish National Research Foundation and President of Copenhagen Research Forum. She is a member of Conseil d'Administration, INSERM, L'Institut National de la Sante et de la Recherdes Medicales, France and also serves on the advisory boards for Wonderful Copenhagen, Medico Innovation, the Arvid Nilssons Foundation and Tagea Brandt.
Mr Denis Horgan
European Alliance for Personalised Medicine, Brussels, Belgium
Denis Horgan is the Executive Director of the European Alliance for Personalised Medicine (EAPM). Launched in March 2012 the EAPM brings together European healthcare experts and patient advocates involved with major chronic diseases. The mission of the EAPM is to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics.
Prior to working with the EAPM, Denis worked with the European Cancer Patient Coalition and in the European Parliament on broad array of health issue relating to pharmaceuticals and patient issues and with international NGOs on health development projects in Afghanistan, Mexico and Palestine. Over the course of his career, he has developed numerous public affairs initiatives in the areas of advocacy, social marketing, policy support and launch, policy development and media relations.
Professor Jacek Jassem
Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
Professor Jassem is the Head of the Department of Oncology and Radiotherapy at the Medical University of Gdansk, Poland. Professor Jassem received his MD and PhD degrees in Gdansk and also trained in oncology at the Karolinska Institute in Stockholm and the National Cancer Institute in Amsterdam.
Jacek’s main scientific interests are lung cancer, breast cancer, combined modality treatment with chemotherapy and radiation as well as molecular oncology. He has (co)authored over 500 full articles, patents, books and book chapters in this field and has also led nationwide public health initiatives, including authoring the Polish anti-tobacco legislation (introduced by the Parliament in 2010) and the coordination of Cancer Control Strategy for Poland 2015-2024.
Professor Jassem is the past-chairman of the EORTC Breast Cancer Group and the EORTC Executive Committee, the chairman of the Central and East European Oncology Group, the past chairman of the ASCO International Affairs Committee, and the immediate past-president of the Polish Oncological Society. He is a member of the European Academy of Cancer Sciences and Polish Academy of Art and Sciences and he is currently an ESMO Executive Board member.
His work has been recognised by several Polish and international scientific awards.
Professor Patrick Johnston
Queens University Belfast, Belfast, United Kingdom
Professor Johnston is President and Vice-Chancellor of Queens University, Belfast. He is a medical oncologist who trained in Belfast and then moved on to a Fellowship at the National Cancer Institute in Bethesda, Maryland. Paddy returned to the UK in 1996, later leading the establishment of the Centre for Cancer Research and Cell Biology and becoming its Director and, subsequently, Dean of the School of Medicine, Dentistry and Biomedical Sciences.
Paddy’s own research focus over 25 years has been on the understanding of mechanisms of drug resistance to therapeutic agents. This has resulted in a number of prestigious landmark publications and more than 20 patents.
In 2012 Professor Johnston received a Diamond Jubilee Queen’s Anniversary Prize from Her Majesty The Queen for his role in the reorganisation of cancer care in Northern Ireland. In 2012 he was also elected to the Fellowship of the Academy of Medical Sciences and in 2013 he was named winner of the international Bob Pinedo Cancer Care Prize, recognising his work in translating discovery science for the benefit of cancer patients.
Professor Johnston is the founder of the Society for Translational Oncology, headquartered in Durham, North Carolina, USA.
Professor Peter Johnson
Department of Medical Oncology, University of Southampton, Southampton, United Kingdom
Cancer Research UK, London, United Kingdom
Professor Peter Johnson is Professor of Medical Oncology within Medicine at the University of Southampton. He trained in oncology at St Bartholomew's Hospital and now leads the Southampton Cancer Research UK Centre, responsible for bringing together a broad multidisciplinary group of basic, translational and clinical researchers.
Peter specialises in the treatment of lymphoma, and is the Chief Investigator for several lymphoma trials nationally and internationally. His research interests include immunotherapy and translational research.
Professor Johnson is CRUK's chief clinician, and has been the chair of the National Cancer Research Institute Lymphoma Studies Group. He was responsible for carrying out the evidence review for the commissioning of haematological malignancy for the Department of Health.
Professor Johnson is contributing editor on lymphoma to The Haematologist, the newsletter of the American Society of Haematology and he is a member of the organising committees for the International Conference on Malignant Lymphoma, Lugano and the International Symposium on Hodgkin Lymphoma, Cologne.
Professor Stein Kaasa
Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim
Professor Kaasa is Professor of Palliative Medicine at the Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim.
Stein’s main research interests include basic research in assessment and classification of symptoms and subjective health, experimental and descriptive clinical studies in palliative medicine and cancer research, and pain treatment including translational research on opioids and on cachexia.
Stein has published more than 300 articles and book chapters. He has authored the Nordic Textbook of Palliative Care and is co-author of the Oxford Textbook of Palliative Medicine. He advises many international journals – either as an advisory board member or as a reviewer
Stein is the chair of the European Palliative Care Research Centre (PRC), which aims to improve palliative patient care, including end of life care, through research of highest quality in an international setting. He is also chair of the European Association for Palliative Care Research Network (EAPC RN) and the International Association for the Study of Pain (IASP) task force on cancer pain, and principal investigator of the European Palliative Care Research Collaborative (EPCRC). Stein is also the National Cancer Director at the Norwegian Directorate for Health.
Dr h.c. Peter Kapitein
Inspire2Live, Amsterdam, The Netherlands
Dr. h.c. Peter Kapitein is a Patient Advocate of Inspire2Live. He connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as internationally. He organises congresses, lobbies the matrix of public authorities, health care organisations, insurance companies and health research institutes. Peter also give lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He writes blogs, articles and books that also contribute to these topics.
Peter was the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez. They raised over 100 million euros for the fight against cancer. Peter works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in his patient advocacy. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam.
Dr Sakari Karjalainen
Association of European Cancer Leagues, Brussels, Belgium
Dr Karjalainen is the President of Association of European Cancer Leagues (ECL) and secretary general of the Cancer Society of Finland. As ECL President Dr Karjalainen is responsible for leading the pan-European cancer control activities of ECL, whose vision is a Europe free of cancers.
Sakari holds a docotorate in medical sciences (epidemiology) His main research interests are research ethics, equity in health and education and cancer epidemiology.
Dr Karjalainen is also leading the EU Joint Action Cancon work package 2 and the EU Joint Action of Rare Cancers work package 3. His previous roles include those of; Director General of the Department of Education and Science Policy of the Ministry of Education and Culture in Finland and Secretary General of Research Council for Health at the Academy of Finland, the main funding organisation for academic research in Finland.
Ms Joan Kelly
Irish Cancer Society, Dublin, Ireland
European Cancer Leagues, Brussels, Belgium
Joan Kelly is the Nursing Services Manager for the Irish Cancer Society, a charity that works across a broad range of activities with the goal to achieving incremental and measurable improvements in cancer outcomes. It does this by supporting world-class research into the nature, causes and potential cures for cancer. It it also supports research into ways to deliver care in better, more effective and more compassionate ways and recognises the importance of education and advocacy in achieving its goals.
Joan trained as an oncology nurse and her specialist skills include; optimising services for cancer patients and their families, cancer information /health literacy, palliative care and patient advocacy.
In addition to her role at the ICS, Joan was a past president of the European Cancer Leagues and a member of the ECCO Patient Advisory Committee.
Ms Anita Kienesberger
Austrian Childhood Cancer Organisation
Anita Kienesberger is the current CEO of the Austrian Childhood Cancer Organisation, a registered charity which provides information and advice to families, raises awareness and provides psychosocial aftercare for children and teenagers suffering from cancer, and their parents and siblings.
Anita’s previous experience includes working as a paediatric oncology nurse. Following this, Anita was the Head of the Intensive Care Unit at St Anna Kinderspital, Vienna. Anita has worked on a number of EU-funded projects for paediatric oncology. She was previously a Board member of the Childhood Cancer International (CCI), and she is currently the Head of the CCI European Regional Committee. Anita is also a member of the ECCO PAC.
Professor Carlo La Vecchia
Professor of Epidemiology and Biostatistics, School of Medicine, University of Milan
Professor La Vecchia received his medical degree from the University of Milan and a master of science degree in clinical epidemiology from Oxford University. He is recognized worldwide as a leading authority in cancer aetiology and epidemiology. Presently, he is Professor of Epidemiology and Biostatistics at the School of Medicine at the University of Milan. Professor La Vecchia serves as an editor for numerous clinical and epidemiologic journals. He is among the most renowned and productive epidemiologists in the field with over 1,950 peer-reviewed papers in the literature (Pubmed) and is among the most highly cited medical researchers in the world, according to ISIHighlyCited.com, the developer and publisher of the Science Citation Index (h index, 136, total IF over 7000, over 120,000 quotations). Professor La Vecchia is an Adjunct Professor of Medicine at Vanderbilt Medical Center and the Vanderbilt-Ingram Cancer Center.
Professor La Vecchia is a temporary advisor at the World Health Organization in Geneva, and a registered journalist in Milan. He was Adjunct Associate Professor of Epidemiology at Harvard School of Public Health between 1996 and 2001 and Adjunct Professor of Epidemiology at the University of Lausanne, CH (2000-14), was Senior Research Fellow at the International Agency for Research on Cancer IARC/WHO between 2006 and 2008, and Head of the Department of Epidemiology at the Mario Negri Institute, Milan between 2007 and 2014.
Professor La Vecchia’s main fields of interest include cancer epidemiology and the risk related to diet, tobacco, hormone use and occupational or environmental exposure to toxic substances; and analysis of temporal trends and geographical distribution of mortality from cancer, cardiovascular diseases, perinatal and other selected conditions.
Professor Thierry Le Chevalier
Institute Gustave Roussy, Paris, France
Professor Le Chevalier is currently Head of Department at the Institute Gustave Roussy, Paris, France.
Dr Le Chevalier was formerly director, international affairs, at the French National Cancer Institute. Prior to this, he held a number of positions at the Institut Gustave Roussy in France including Head of the Division of Cancer.
Thierry research interests include therapeutic strategies for lung cancer, development of new cancer dugs and translational research. He has written and contributed to more than 300 publications, presentations and books and he is currently the associate editor of Annals of Oncology and the Journal of Thoracic Oncology. He has previously held the position of chairman of both the Lung Cancer Group of the French Federation of Cancer Centres and the Scientific Committee of the French Intergroup of Thoracic Oncology. From 2006-2009, Professor Le Chevalier was Vice-President and Scientific Advisor Oncology GSK Europe (London).
Dr Tomas Lindahl
Emeritus Group Leader, Francis Crick Institute, London, United Kingdom
Dr Lindahl is a Swedish scientist specialising in DNA damage and repair. He studied for his PhD and MD at the Karolinska Institute and his post-doctoral research was carried out at Princeton and Rockefeller Universities. From 1986 to 2005 he was the first Director of Cancer Research UK's Clare Hall Laboratories in Hertfordshire, (now part of the Francis Crick Institute). Tomas closed his lab at the Clare Hall laboratories in 2009 but remains an Emeritus Group Leader at the Francis Crick Institute.
Tomas’ Mutagenesis Laboratory at Clare Hall characterised different DNA repair pathways to provide a better understanding of the cellular defence mechanisms against damage to the human genome.
Professor Lindahl outstanding research has been recognised by many honours and awards including; the Copley medal, the Royal Society's Royal Medal, the INSERM Prix Etranger and, in 2015, he was the joint recipient of the Nobel Prize for Chemistry.
Professor Bob Löwenberg
Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
Professor Löwenberg is Professor of Haematology at Erasmus University Medical Centre in Rotterdam, the Netherlands. He completed his initial training at Groningen University and he received his PhD from Erasmus University before continuing his research at UCLA. From to 1982 to 1990, he served as Scientific Director of the Daniel den Hoed Cancer Centre.
Bob’s research is focused on the treatment and the pathobiology of leukaemia and hematopoietic stem cell transplantation. He has published widely in leading scientific journals in the area of developmental diagnostics and therapeutics and he is the Editor-in-Chief of Blood, the leading scientific journal in hematology. He is the founder and chair of the European HOVON Leukaemia Cooperative group.
He served as president of the European Association of Hematology (EHA), the International Society of Experimental Haematology and the International Society of Haematology and currently serves as the Scientific Chair of the European School of Hematology (Paris). He is an elected Member at the Royal Academy of Sciences and Arts of The Netherlands.
Professor Löwenberg has received several awards including the Dr. P Muntendam Cancer Prize of the Netherlands Cancer Society (Amsterdam), the Jacqueline Seroussi Memorial Foundation for Cancer Research Award (Tel Aviv) and the EHA Jean Bernard Lifetime Award (London) for his scientific contributions in the field of leukaemia.
Professor Lucio Luzzatto
Professor of Haematology, Muhimbili University College of Health Sciences, Dar-es-Salaam, Tanzania
Honorary Professor, University of Firenze, Florence, Italy
Professor Luzzatto is currently a Visiting Professor at the Muhimbili University Hospital in Dar es Salaam, Tanzania. The main aim of his research has been to understand in depth blood diseases for the ultimate purpose of improving their management.
Lucio holds multiple honours and awards, and he was recently awarded the Accademia dei Lincei Annual Prize in Biology. Lucio has published over 300 papers in international scientific journals, and he has authored many chapters in major textbooks.
Professor Rebecca Malby
School of Health and Social Care, London South Bank University, London, United Kingdom
Professor Malby is Professor in Health Systems Innovation at London South Bank University. She started her career in clinical work, moving into managerial, research and organisational change posts in the NHS, at Trust through to Regional levels. She has an MA in Public and Social Policy. Until recently she was the Director of the Centre for Innovation in Health Management (CIHM) at the University of Leeds where she also took a leadership role in the Leeds Institute for Quality Healthcare.
Becky is currently an advisor to the Kings Fund/ Health Foundation Readiness for Change Programme, and on the Advisory Board of The Bromley By Bow Unleashing Health Communities Programme, the Scaling up Shared Lives in Healthcare Programme Implementation Group, and the Health Foundation Shared Haemodialysis Care Programme. Becky is a nominator for the Ashoka network.
She has a track record in organisational and leadership development in the public sector, working primarily with the NHS and with local authorities in the UK and Europe.
Becky is a Visiting Associate at Stellenbosch University School of Public Leadership, and a Director of the Social Enterprise incLucid.
Mr Ken Mastris
Chairman - Chairman of Europa Uomo
Ken Mastris is a patient advocate, committed to promoting patient pathways and awareness of prostate cancer after he was diagnosed in 2005. Ken is the Chairman of Europa Uomo, a coalition of over 20 European organisations dedicated to improving knowledge of prostate cancer. He is also the Secretary of Tackle Prostate Cancer UK, and the Chairman of APPLE, a local charity for prostate cancer. Ken is an ECCO PAC member.
Professor Françoise Meunier
European Organisation for Research and Treatment of Cancer, Brussels, Belgium
Professor Meunier was Director General of the European Organisation for Research and Treatment of Cancer, from 1991 to April 2015 and continues as leader of special projects. She received her medical degree, Masters and PhD from the Université Libre de Bruxelles (ULB) and completed her research fellowship at the Memorial Sloan-Kettering Cancer Center in New York. Professor Meunier led the coordination and administration of all EORTC activities since 1991 with the mandate to promote the EORTC as a major European organisation in the field of oncology with a network of 2,500 oncologists in over 300 universities and a Headquarters staff of 160 representing 17 different nationalities.
Before joining the EORTC Françoise was Head of the Infectious Disease Department at the Institut Jules Bordet in Brussels and her personal area of research focused on Invasive Fungal Infections in Cancer Patients. She has over 150 peer-reviewed published articles and is a member of numerous international oncology scientific societies.
Professor Meunier has received numerous awards in recognition for her unique contribution to oncology and for the dedication of her professional life to the improvement of cancer treatment, care and research, including;
the Belgian Laureate “Prix Femmes d’Europe. She is a Fellow of the Royal College of Physicians UK, a Fellow of the European Academy of Cancer Sciences, a member of the Belgian Royal Academy of Medicine (Académie Royale de Médecine de Belgique) and, in 2007, she was awarded the honorary title of Baroness by His Royal Majesty King Albert II of Belgium. She received an Honorary Degree from Queen’s University Belfast in 2015
Dr Martin Murphy
Society for Translational Oncology
Martin Murphy is the co-founder of the Society for Translational Oncology. Since January 2000 he has held the position of Chief Executive Officer of the non-profit CEO Roundtable on Cancer. He is also Founding Chairman and Chief Executive Officer of AlphaMed Consulting.
Dr Murphy has authored over 150 peer-reviewed papers. He is the Founding Executive Editor of three peer-reviewed journals; The Oncologist, Stem Cells and Stem Cells Translational Medicine.
Dr Murphy is a charter member of the International Advisory Board of the VU University Medical Imaging Center. He is also a charter member of Queen’s University Belfast School of Medicine International Review Board. Dr Murphy is the convener of Advanced Clinical Trials-China, and a Steering Committee Member and Senior Consultant of the Chinese Society of Clinical Oncology.
Professor Peter Naredi
Department of Surgery, University of Gothenburg
Peter Naredi is Professor of Surgery and Chairman of the Department of Surgery at the Sahlgrenska Academy, University of Gothenburg. Before taking in this position in 2012 he spent time in post-doctoral studies at the University of California, San Diego and was Professor of Surgery at Umea University in Sweden.
Peter’s main research interests include immunotherapy and the treatment of primary and secondary liver tumours and pancreatic cancer.
He is President of ECCO, the European CanCer Organisation, Past-President of ESSO and is Scientific Chair of the ECCO Congress 2017 in Amsterdam.
Professor Sir Paul Nurse
Francis Crick Institute, London, United Kingdom
Professor Nurse was appointed as the first Director and Chief Executive of the Francis Crick Institute in London in 2011. Having completed degrees at the Universities of Birmingham and East Anglia, Sir Paul has worked in a number of scientific institutions during his career including the universities of Bern, Edinburgh, Sussex and Oxford. In 1996 he became Director General of the ICRF, the Chief Executive of Cancer Research UK in 2002 and, in 2013, he became the President of Rockefeller University in New York City. In 2010 Sir Paul became President of the Royal Society stepping down in 2015.
Paul is a geneticist and cell biologist whose discoveries have helped to explain how the cell controls its cycle of growth and division.
Professor Nurse’s outstanding scientific achievements have been recognised by numerous awards and prizes including; a Fellow of the Royal Society (FRS) and a foreign associate of the US National Academy of Sciences. He was awarded the French Legion d'Honneur in 2002 and in 2013 he became the winner of the Albert Einstein World Award of Science conferred by the World Cultural Council. He has been a member of the Council for Science and Technology, advising the Prime Minister since 2000.
Paul was knighted in 1999 and awarded the 2001 Nobel Prize in Physiology or Medicine (with Leland Hartwell and Sir Tim Hunt).
(Photo credit - Fiona Hanson/AP Images)
Ms Kathy Oliver
International Brain Tumour Alliance, Tadworth, Surrey, United Kingdom
Kathy Oliver is Chair and founding Co-Director of the International Brain Tumour Alliance (IBTA), a unique global network for brain tumour patient and caregiver groups around the world. The IBTA works alongside researchers, scientists, clinicians, nurses, allied healthcare professionals and other stakeholders to engage in advocacy, to raise awareness and to share information.
Kathy, a frequent speaker at international neuro-oncology and cancer conferences, is a founder-member of Rare Cancers Europe; Vice-Chair of the European CanCer Organisation’s (ECCO) Patient Advisory Committee (PAC); Co-Chair of the Project Advisory Board for the European Patients’ Academy on Therapeutic Innovation (EUPATI); a member of the Council of the British Neuro-Oncology Society (BNOS), having also served on the BNOS Rare Brain Tumours Guidelines Group; a member of the European Society of Medical Oncology’s (ESMO) Patient Advocacy Working Group (PAWG); a founder member/former Board member of Cancer52 (the UK umbrella organisation for nearly 100 rare cancer patient organisations) and a member of the UK NCRI Brain Tumour Palliative and Supportive Care Subgroup. Kathy serves on the European Association of Neuro-Oncology (EANO) Guidelines Task Force on Palliative/Supportive/End-of-Life Care and is the Cochrane Consumer Referee for the Cochrane Neuro-Oncology Group. She also serves on the European Commission’s Expert Group on Cancer Control.
Kathy’s son, Colin, was diagnosed with a brain tumour in 2004 at age 24 and passed away, at age 32, in August 2011. She cites her son’s “incredible courage, determination and fortitude” as the driving force and inspiration behind her involvement in the international brain tumour and rare cancer community.
Mr Jonathan Pearce
Chief Executive – Lymphoma Association, United Kingdom
Jonathan Pearce joined Lymphoma Association as Chief Executive in 2013. He has over 10 years’ experience as a charity Chief Executive, having worked previously at Cabrini Children’s Society and Adoption UK.
He is Chair of Cancer52, a national alliance of charities representing rare and less common cancers. He is also an Executive Board member of the Lymphoma Coalition, the global network of lymphoma patient groups. Jonathan is an ECCO PAC member.
Jonathan has a background in the voluntary sector, law, publishing and journalism. His previous experience includes working at the Legal Action Group and also for Community Care magazine where he worked as a journalist.
Ms Jana Pelouchová
European Cancer Patient Coalition
Jana Pelouchová was diagnosed with chronic myeloid leukaemia (CML) and the challenges of living with CML led her to establish the patient organisation Diagnoza CML in 2006. This evolved into Diagnoza Leukemie in 2014, addressing patients with all types of leukaemias. In 2007 Jana became the co-founder of the CML Advocates Network. She is also the president of the Swiss-based Leukaemia Patient Advocates Foundation.
Jana is an ECPC Board Member and Secretary, and is also a member of the ECCO PAC.
Professor Martine Piccart
Jules Bordet Institute, in Brussels, Belgium
Professor Piccart is Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium. She earned her medical degrees at the ULB and her oncology qualifications in New York and London.
Martine’s primary research interests are in breast cancer and drug development and she is a leader in international research collaboration acting as the principal or co-principal investigator of a number of practice changing clinical trials. She is co-founder and chair of the Breast International Group (BIG), uniting 47 academic research groups from around the world and running over 30 trials under its umbrella. Martine has (co)authored more than 390 publications in peer-reviewed journals.
Professor Piccart is active in numerous professional organisations. She is past-President of the EORTC, served on the ASCO Board and is past President of ECCO and a member of the Belgian Royal Academy of Medicine. She has received numerous prestigious awards for her research contributions including the Jill Rose Award (New York) and the William L. McGuire Award (San Antonio).
Professor Bob Pinedo
VuMC Cancer Center, Amsterdam, The Netherlands
Professor Pinedo is Emeritus Professor of Medical Oncology at VU University Amsterdam and served for more than 25 years as chief of the VUmc Department of Oncology where he still practices medical oncology. He was one of the founders of the Centre for Translational Molecular Medicine in Eindhoven, Netherlands, in 2006 and continues to serve on its supervisory board. He also holds visiting professor positions at Johns Hopkins University and the Technical University Twente, Netherlands.
In a career spanning four decades, Bob has focused on original, translational cancer research combining leading-edge basic science with clinical excellence. Professor Pinedo was present at the birth of modern medical oncology and was a pioneer in bridging the gap between laboratory and clinical practice. As a clinical investigator taking new concepts into early clinical trials, he has made seminal observations in cancer biology the mode of action of anti-cancer drugs and drug resistance. His activities in the Early Clinical Trials Group of the European Organization for Research and Treatment of Cancer (EORTC) merit particular mention.
Recognition of Professor Pinedo’s work takes the form of countless honorary memberships and prizes, as well as grants from Dutch and foreign institutions. He is a member of many international associations and is on the editorial boards of fourteen international journals. Awards include the Bristol-Meyers Squibb Foundation Cancer Grant Award the International Chiron Award for Bioclinical Research and Training and the prestigious Jozef Steiner Award. He was the the 2014 recipient of the (ASCO) David A. Karnofsky Memorial Award.
Mrs Gilly Spurrier-Bernard
Melanoma Patient Network Europe
Gilly Spurrier-Bernard has been involved with melanoma since her husband was diagnosed 7 years ago. She founded Melanome France and a Closed Francophone patient group dedicated to addressing patients’ needs. Gilly is a core member of Melanoma Patients Network Europe, and is passionate about patients being educated partners in their treatment. Gilly is a member of the ECCO PAC.
Professor Richard Sullivan
Institute of Cancer Policy, Kings Health Partners Integrated Cancer Centre, London, United Kingdom
Professor Sullivan is Director of the Institute of Cancer Policy and KHP Integrated Cancer Centre global health work. He also teaches on the conflict and security module of the Global Health iBSc and is the cancer lead for the King’s Sierra Leone Partnership. He was formerly Clinical Director of Cancer Research UK, including leading their global health policy research and was past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank.
Richard’s research programmes extend from the public policy of global cancer, to the development of care and research systems in emerging economies and the development
Professor Josep Tabernero
Vall D’Hebron Institute of Oncology, Barcelona, Spain
Professor Tabernero holds MD and PhD degrees from the Universitat Autonoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology.
Joseph’s research interests are focussed on translational research and phase I studies with molecular targeted therapies and personalised medicine. He has (co)authored approximately 250 peer-reviewed papers and has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings. He is a member of the ESMO Magnitude of Clinical Benefit Scale Working Group, the ESMO Public Policy Steering Committee and the ESMO Audit Committee.
Professor Tabernero is a member of the Executive Board of the European Society for Medical Oncology (ESMO), and was Treasurer and Chair of Audit Committee until 2015. He has been elected ESMO President 2018-2019 and is currently serving as President-elect.
Professor Cornelis Van de Velde
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
Professor van de Velde is Professor of Surgical Oncology at the Leiden University Medical Center, Leiden, the Netherlands. He received his training at the Leiden University Medical Center in Leiden, has worked at the M.D. Anderson Hospital in Houston and was a visiting Professor at the Seoul National University Hospital in Korea and at the National Cancer Center Hospital in Tokyo, Japan.
Cornelis’ primary areas of research interests include breast, colorectal, gastric cancer and endocrine tumours. He has led on numerous national and international clinical trial and authored more than 600 publications.
Throughout his career Professor van de Velde’s work has been recognised through numerous awards, prizes and honours. He was appointed a Member of the Royal Academy of Sciences of the Netherlands and since 2004 has served as President of the Medical Section. From 2008 to 2010, he was President of the European Society of Surgical Oncology (ESSO), then President of ECCO - the European CanCer Organisation in 2012 and 2013.
Mr Bert van Herk
ECCO Patients Advisory Committee
Bert van Herk was diagnosed with lung cancer in 2000 and at the end of 2015 he stopped working in healthcare management to focus on patient advocacy. Bert was appointed as Chair of the Patient Advisory Committee of Spaarne Gasthuis, one of the leading hospitals in The Netherlands. Bert is an ECCO PAC member.
Professor Peter Vedsted
Institute for Public Health, Aarhus University
University Clinic for Innovative Health Care Delivery, Silkeborg Hospital, Department of Clinical Medicine, Aarhus University, Denmark
Since June 2015 Professor Vedsted has worked at the Diagnostic Centre in Silkeborg Hospital, which is dedicated to research on innovative patient pathways and rational diagnostics. He is also the Director of the Research Centre for Cancer Diagnosis in Primary Care. The research centre conducts research into the pathway from the first symptom to the start of treatment for cancer patients.
Between May 2011 and March 2016, Professor Vedsted was the Editor-in-Chief of the Scandinavian Journal of Primary Health Care. He has authored or coauthored more than 200 journal articles.
Mrs Anita Waldmann
In 1992 Anita Waldmann lost her son, age 27, after two years suffering with acute lymphocytic leukaemia. Since then she has dedicated her life to care and advocate for patients with blood and lymphatic diseases and their relatives.
Anita founded the local Leukaemia Patient-Support Group (LHRM) in 1991. She was the founding member of the Deutsche Leukaemie and Lymphom-Hilfe (DLH) in 1995. From 2001 to 2008 she was the chairwoman of the DLH and also a member of the patients’ advisory board of the Deutsche Krebshilfe (German Cancer Aid). She was also a member of the cancer plan steering committee of the Deutsche Krebsgesellschaft (German Cancer Association).
Anita is a member of the ESMO and ECCO Patient Advisory Committees
Professor David Weller
Centre for Population Health Sciences, University of Edinburgh, United Kingdom
Professor Weller is Head of the General Practice Section in the Division of Community Health Sciences at the University of Edinburgh. His medical studies were completed the University of Adelaide Medical School with post-graduate studies in Adelaide and Nottingham. He has been James Mackenzie Professor of General Practice at the University of Edinburgh since 2000 and Head of the School of Clinical Sciences and Community Health from 2005-2012.
David’s research interests include primary care oncology and medically unexplained symptoms in primary care and he is also interested in screening, early diagnosis and prevention. He leads the Cancer and Primary Care Research International Network (CA_PRI) promoting international research collaboration, is a member of the National Cancer Research Institute Primary Care Clinical Studies Development Group (Chair from 2007-2010) and is actively engaged in activities to build capacity in primary care and cancer research in the UK.
David sits on a number of Scottish and UK cancer advisory boards.
Professor Nils Wilking
Department of Oncology, Karolinska Institut, Stockholm, Sweden, and Skane University Hospital, Lund, Sweden
Associate Professor Nils Wilking has worked in clinical oncology for 30 years after graduating from the Karolinska Institute in Stockholm, Sweden. He spent a number of years working in senior positions in the pharmaceutical industry while maintaining an academic relationship with the Karolinska and, in 2013, was appointed as the head of the department of oncology at Skanes University Hospital, Lund/ Malmö Sweden. Professor Wilking also serves as a Senior Strategic Advisor for the Southern Health Care Region in Sweden.
Nils initially worked in the field of surgical oncology but has, since the late 1980s, mainly worked within medical oncology with a focus on breast and GI cancer. He was responsible for establishing and heading the cancer clinical trials unit at the Karolinska Hospital.
More recently Professor Wilking’s main interest has been in international research in relation to health service delivery. This work (in collaboration with Professor Bengt Jönsson) has resulted in a number of reports with a focus on patient’s access to cancer therapy.
Mr Roger Wilson
President, Sarcoma Patients Euronet
Roger Wilson is a cancer survivor and patient advocate having been diagnosed with a soft tissue sarcoma in 1999. Three years after his diagnosis, Roger and his wife, Sheelagh, started work on what has become Sarcoma UK. Prior to being diagnosed with sarcoma, Roger worked as a journalist and consultant in the competitive TV and telecommunications industry. Earlier in his career he worked in production for BBC TV (1964 to 1980) and as an independent producer (1980 to 1990).
Roger has a special interest in research and has been a member of the UK’s National Cancer Research Institute’s Board and chaired the national patient group in research. He has also been active with NICE, most recently as the patient expert on the development of Quality Standards for Sarcoma. Roger also worked with Professor Sir Mike Richards, the former National Cancer Director, as a member of his Advisory Board for five years. Roger still works with Sarcoma UK as one of its Sarcoma Voices. He is currently involved with a number of national and international organisations including; the National Cancer Research Institute (NCRI) Sarcoma Clinical Studies Group, the External Advisory Board of the Wales Cancer Research Centre, as President of Sarcoma Patients Euronet (SPAEN) and as a member of the NCRI Consumer Forum.
Roger received a CBE in the New Year Honours list in January 2011 for services to healthcare. He also has honorary doctorates from the Universities of Sheffield and Lancaster. He was elected a Member of Cancer Research UK in 2015.
Dr Wendy Yared
Association of European Cancer Leagues, Brussels, Belgium
Dr Yared is Director of the Association of European Cancer Leagues (ECL), a pan-European alliance of national and regional cancer leagues. ECL facilitates the collaboration among cancer leagues throughout Europe and influences EU and pan-European policies by working closely with the European Commission and European Parliament.
Wendy has more than 25 years’ experience in public health. She was previously with the World Health Organisation, worked with the European Parliament and the United States Public Health Service and is an advisor on international health systems and policy issues.
At the EU level, Wendy is on the Commission’s Expert Group on Cancer Control and is an Associated Partner of the current European Commission Joint Action in Cancer Control (Cancon 2014-2017). She was previously the leader for the Health Promotion and Prevention work package within the last JointAction Partnership for Action Against Cancer in 2011-2014. Dr Yared is active in the Commission’s Platform on Diet, Physical Activity and Health, as well as a founding member of the EU Alcohol and Health Forum.
Professor Christoph Zielinski
Comprehensive Cancer Center and Department of Medicine I, Medical University Vienna, General Hospital, Vienna, Austria
Professor Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine at Medical University Vienna, Austria. He serves as Director of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria, and is President of the Central European Cooperative Oncology Group. Professor Zielinski completed his medical training at the University Hospital Vienna and began his career as a research fellow at Tufts University, Boston, USA.
Christoph’s recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published over 550 original papers and reviews in peer-review journals and is a member of the editorial board of numerous peer review journals.
Professor Zielinski is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and is a member of the Executive Board of the European Society for Medical Oncology (ESMO). Professor Zielinski is the Editor-in-Chief of ESMO Open - Cancer Horizons.
Professor Harald zur Hausen
German Cancer Research Centre, University of Heidelberg, Heidelberg, Germany
Professor zur Hausen is now retired but was, for many years, the Chairman of the German Cancer Research Centre (DKFZ) and Honorary Professor of the University of Heidelberg and still retains an active interest in health matters. He studied medicine in Bonn, Hamburg and Düsseldorf and also worked at the Children’s Hospital in Philadelphia. On 1 January 2010 zur Hausen became the president of the German Cancer Aid, the leading organization fighting cancer in Europe.
Harald’s focus of research has been in the study of oncoviruses, in particular, how cervical cancer is triggered by virus infections. His identification of HPV16 and HPV18 in cervical cancers made possible the development of a vaccine which was introduced in 2006. He is also credited with discovery of the virus causing genital warts (HPV 6) and a monkey lymphotropic polyomavirus that is a close relative to a recently discovered human Merkel cell polyomavirus.
Harald zur Hausen has received several national and international awards for his contributions to medical science and is a holder of the Grand Federal Cross of Merit. In 2008, Professor zur Hausen was awarded the Nobel Prize for medicine.